Treatment outcome of patients with brain metastases from malignant germ cell tumors

Cancer

Volumn 85, Issue 4, 1999, Pages 988-997

  Fosså, Sophie D ^a   Bokemeyer, Carsten ^b   Gerl, Arthur ^c   Culine, Stephane ^d   Jones, William G ^e   Mead, Graham M ^f   Germa Luch, José R ^g   Pont, Jörg ^h   Schmoll, Hans J ⁱ   Tjulandin, Sergei ^j  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^f ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^h Wilhelminenhospital Vienna   (Austria)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

more..

Author keywords

Brain metastases; Chemotherapy; Malignant germ cell tumors; Prognostic factors; Radiotherapy; Survival

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BRAIN NEOPLASMS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; GERMINOMA; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033557960     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990215)85:4<988::AID-CNCR29>3.0.CO;2-R     Document Type: Article

References (22)

1. International Germ Cell Cancer Collaborative Group (IGC-CCG). The International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer. J Clin Oncol 1997;15:594-603.
2. Gerl A, Clemm C, Kohl P, Schalhorn A, Wilmanns W. Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer. Clin Exp Metastasis 1994;12:226-30.
3. Bower M, Newlands ES, Holden L, Rustin GJS, Begent RHJ. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 1997;8:477-83.
4. Logothetis CJ, Samuels ML, Trindade A. The management of brain metastases in germ cell tumors. Cancer 1982;49:12-8.
5. Raghavan D, Mackintosh JF, Fox RM, Rogers J, Duval P, Besser M. Improved survival after brain metastases in non-seminomatous germ cell tumours with combined modality treatment. Br J Urol 1987;60:364-7.
6. Rustin GJS, Newlands ES, Bagshawe KD, Begent RHJ, Crawford SM. Successful management of metastatic and primary germ cell tumors in the brain. Cancer 1986;57:2108-13.
7. Spears WT, Morphis JG, Lester SG, Williams SD, Einhorn LH. Brain metastases and testicular tumors: long-term survival. Int J Radiat Oncol Biol Phys 1991;22:17-22.
8. James PPB, Mead GM. Sanctuary site relapse in chemotherapy-treated testicular cancer. Ann Oncol 1992;3:41-3.
9. Raina V, Singh SP, Kamble N, Tanwar R, Rao K, Dawar R, et al. Brain metastasis as the site of relapse in germ cell tumor of testis. Cancer 1993;72:2182-5.
10. Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, et al. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 1997;15:1449-54.
11. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40.
12. Peckham MJ, Barrett A, Liew KH, Horwich A, Robinson B, Dobbs HJ, et al. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer 1983;47:613-9.
13. Lewis CR, Fosså SD, Mead G, ten Bokkel Huinink W, Harding MJ, Mill L, et al. A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 1991;2:203-11.
14. Collins DH, Pugh RCB. The pathology of testicular tumours. Br J Urol 1964;36(Suppl):1-112.
15. Ginsberg S, Kirshner J, Reich S, Panasci L, Finkelstein T, Fandrich S, et al. Systemic chemotherapy for a primary germ cell tumour of the brain: a pharmacokinetic study. Cancer Treat Rep 1981;65:477-83.
16. Stewart OJ, Richard M, Hugenholtz H, Dennery J. VP-16 (VP) and VM-26 (VM) penetration into human brain tumours (BT). Proc Am Assoc Cancer Res 1983;24:133.
17. Balmaceda C, Heller G, Rosenblum M, Diez B, Villablanca JG, Kellie S, et al. Chemotherapy without irradiation - a novel approach for newly diagnosed CNS germ cell tumors: results of an International Cooperative Trial. J Clin Oncol 1996;14:2908-15.
18. Bokemeyer C, Schmoll HJ. Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoetic growth factors or peripheral blood stem cells (PBSC). Eur Urol 1993;23:223-30.
19. Broun E, Nichols CR, Turns M, Einhorn LH. First line salvage therapy and high dose chemotherapy with autologous bone marrow rescue (ABMR) for germ cell cancer [abstract 702]. Proc Am Assoc Clin Oncol 1993;12:229.
20. Rustin GJS, Newlands ES, Begent RHJ, Dent J, Bagshawe KD. Weekly alternating Etoposide Methotrexate, and Actinomycin/Vincristine and Cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989;7:900-3.
21. Motzer R, Bajorin DF, Schwartz LH, Hutter HS, Bosl GJ, Scher HI, et al. Phase II trial of paclitaxel shows antitumour activity in patients with previously treated germ cell tumours. J Clin Oncol 1994;12:277-83.
22. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994; 12:627-42.